tenidap has been researched along with HIV Coinfection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arechavaleta-Velasco, F; Elovitz, MA; Koi, H; Parry, S; Zhang, J | 1 |
| Chapman, B; Cheng, SL; Crumpacker, CS; Dezube, BJ; Dogon, AL; Georges, DL; Lederman, MM; Mudido, P; Reis-Lishing, J; Silberman, SL | 1 |
1 trial(s) available for tenidap and HIV Coinfection
| Article | Year |
|---|---|
The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.
Topics: Acute-Phase Proteins; Adult; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; CD4 Lymphocyte Count; Cross-Over Studies; Cytokines; Double-Blind Method; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indoles; Interleukin-1; Interleukin-6; Oxindoles; RNA, Viral; Serum Amyloid A Protein; Tumor Necrosis Factor-alpha; Viral Load | 1997 |
1 other study(ies) available for tenidap and HIV Coinfection
| Article | Year |
|---|---|
Transcytosis of Human immunodeficiency virus 1 across the placenta is enhanced by treatment with tumour necrosis factor alpha.
Topics: Anti-Inflammatory Agents, Non-Steroidal; CD4 Antigens; Cell Line; Cells, Cultured; Flow Cytometry; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Immunohistochemistry; Indoles; Leukocytes, Mononuclear; Oxindoles; Placenta; Polymerase Chain Reaction; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Trophoblasts; Tumor Necrosis Factor-alpha | 2006 |